- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05551273
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
April 16, 2024 updated by: National Institute of Allergy and Infectious Diseases (NIAID)
Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening.
The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
A5394 is a phase II, double-blinded, placebo-controlled trial.
Forty-eight study participants will be randomized 3:1 to receive SLGN or its placebo (36 active and 12 placebo), and randomization will be stratified by HBeAg status.
One-half of the study participants will be HBeAg positive (n=24) at screening, and the other half will be HBeAg negative (n=24).
All participants will remain on their non-study-provided antiviral therapy throughout the study.
Study Type
Interventional
Enrollment (Estimated)
48
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jennifer Price, MD, PhD
- Phone Number: 415-502-1429
- Email: jennifer.price@ucsf.edu
Study Locations
-
-
South-East District
-
Gaborone, South-East District, Botswana
- Not yet recruiting
- Gaborone CRS
-
-
-
-
-
Porto Alegre, Brazil, 91350-200
- Not yet recruiting
- Hospital Nossa Senhora da Conceicao CRS
-
Rio De Janeiro, Brazil, 21040-360
- Not yet recruiting
- Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS Site ID# 12101
-
Contact:
- Brenda Hoagland, M.D.
- Phone Number: 55-21-38659122
- Email: brenda.hoagland@ini.fiocruz.br
-
Rio de Janeiro, Brazil, 21040-360
- Not yet recruiting
- Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
-
-
-
-
-
Port-au-Prince, Haiti, HT-6110
- Not yet recruiting
- GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS
-
-
-
-
-
Lima, Peru, 04
- Not yet recruiting
- Barranco CRS
-
-
-
-
-
Cavite, Philippines, 4114
- Not yet recruiting
- De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC)
-
-
-
-
-
Durban, South Africa, 4091
- Not yet recruiting
- Durban International CRS
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 1862
- Not yet recruiting
- Soweto ACTG CRS
-
-
-
-
-
Chiang Mai, Thailand, 50200
- Not yet recruiting
- Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS
-
-
Bangkok
-
Pathum Wan, Bangkok, Thailand, 10330
- Not yet recruiting
- Thai Red Cross AIDS Research Centre (TRC-ARC) CRS
-
Contact:
- Parawee Thongpaeng
- Phone Number: 106 662-6523040
- Email: parawee.t@hivnat.org
-
-
-
-
-
Kampala, Uganda
- Not yet recruiting
- Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35222
- Not yet recruiting
- Alabama CRS
-
Contact:
- Faye Heard, M.P.H.
- Phone Number: 205-996-4405
- Email: fhoward@uabmc.edu
-
-
California
-
San Diego, California, United States, 92103
- Recruiting
- UCSD Antiviral Research Center CRS
-
San Francisco, California, United States, 94143
- Recruiting
- Univ of California, San Francisco
-
Torrance, California, United States, 90502
- Not yet recruiting
- Harbor-UCLA Med. Ctr. CRS (Site ID: 603)
-
Contact:
- Mario Guerrero
- Phone Number: 7318 424-201-3000
- Email: mguerrero@lundquist.org
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado Hospital CRS
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20005
- Not yet recruiting
- Whitman-Walker Health CRS
-
Contact:
- Avery Anna Wimpelberg, B.A., CCRC
- Phone Number: 202-797-3589
- Email: AWimpelberg@whitman-walker.org
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Not yet recruiting
- The Ponce de Leon Center CRS
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University CRS
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Not yet recruiting
- Johns Hopkins University CRS
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Not yet recruiting
- Massachusetts General Hospital CRS (MGH CRS)
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Not yet recruiting
- Washington University Therapeutics (WT) CRS
-
-
New Jersey
-
Newark, New Jersey, United States, 07103
- Not yet recruiting
- New Jersey Medical School Clinical Research Center CRS
-
-
New York
-
New York, New York, United States, 10032-3732
- Not yet recruiting
- Columbia P&S CRS
-
New York, New York, United States, 10065
- Not yet recruiting
- Weill Cornell Uptown CRS
-
New York, New York, United States, 10011
- Recruiting
- Weill Cornell Chelsea CRS
-
Rochester, New York, United States, 14642
- Not yet recruiting
- University of Rochester Adult HIV Therapeutic Strategies Network CRS
-
Contact:
- Susan Hulse
- Phone Number: 585-275-0529
- Email: susan_hulse@urmc.rochester.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Not yet recruiting
- Chapel Hill CRS
-
Greensboro, North Carolina, United States, 27401
- Not yet recruiting
- Greensboro CRS
-
-
Ohio
-
Cincinnati, Ohio, United States, 452292899
- Not yet recruiting
- Cincinnati Children's Hosp / Univ Hosp
-
Cleveland, Ohio, United States, 44106
- Recruiting
- Case CRS Site ID# 2501
-
Contact:
- Julie Pasternak, R.N.
- Phone Number: 216-844-2738
- Email: pasternak.julie@clevelandactu.org
-
Columbus, Ohio, United States, 43210
- Not yet recruiting
- Ohio State University CRS
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Not yet recruiting
- Penn Therapeutics CRS
-
Contact:
- Jamie Doyle, MPH, CCRC
- Phone Number: 215-615-2316
- Email: Jamie.Doyle1@pennmedicine.upenn.edu
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- Univ of Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, United States, 37204
- Not yet recruiting
- Vanderbilt Therapeutics (VT) CRS
-
-
Texas
-
Houston, Texas, United States, 77030
- Not yet recruiting
- Houston AIDS Research Team CRS
-
Contact:
- Maria Laura Martinez
- Phone Number: 713-500-6718
- Email: Maria.L.Martinez@uth.tmc.edu
-
-
Washington
-
Seattle, Washington, United States, 98104-9929
- Not yet recruiting
- University of Washington AIDS CRS
-
-
-
-
Harare
-
Milton Park, Harare, Zimbabwe
- Not yet recruiting
- Milton Park CRS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- HIV-1 infection
- Effective antiviral therapy for HIV (ART) and HBV that includes TDF, TAF, TDF/FTC, TDF/3TC (tenofovir disoproxil fumarate plus lamivudine), TAF/FTC, or entecavir (ETV), for ≥5 years immediately prior to study entry. ART is defined as including a minimum of two anti-HIV antivirals.
- CD4+ cell count ≥350 cells/mm3
- HIV-1 RNA <50 copies/mL measured on at least two occasions at least 12 weeks apart, with no documented value >200 copies/mL, over the 12 months prior to study entry.
- Positive or negative HBeAg
- Negative anti-HDV
- Current CHB infection
- HBV DNA level <50 IU/mL measured on at least two occasions at least 12 weeks apart, with no documented value ≥50 IU/mL, over the 12 months prior to study entry.
- Quantitative HBsAg >1000 IU/mL
- Hepatitis C virus (HCV) antibody negative, or if the participant is HCV antibody positive, an undetectable HCV RNA.
- Participants age ≥18 years and ≤70 years at study entry
- Participants must agree to stay on an effective antiviral therapy for HIV (ART) and HBV throughout the study.
Exclusion Criteria:
- Receipt of treatment for HCV within 24 weeks prior to study entry
- Evidence of advanced fibrosis or cirrhosis (Metavir ≥F3 or equivalent).
- Current or prior history of clinical hepatic decompensation (e.g., ascites, encephalopathy, or variceal hemorrhage)
- History of HCC or cholangiocarcinoma
- Malignancy within 5 years prior to study entry. NOTE: A history of non-melanoma skin cancer (e.g., basal cell carcinoma or squamous cell skin cancer) is not exclusionary.
- History of solid organ transplantation
- Presence of any active or acute AIDS-defining opportunistic infections within 60 days prior to study entry
- History of uveitis or posterior synechiae
- Breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
Selgantolimod 3 mg once weekly for 24 weeks
|
1.5 mg tablet
|
Placebo Comparator: Arm B
Matching Placebo for Selgantolimod once weekly for 24 weeks
|
Matching placebo tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of participants who experienced adverse events (AEs)
Time Frame: From study treatment initiation to Week 24
|
From study treatment initiation to Week 24
|
Proportion of participants who prematurely discontinued treatment due to adverse events (AEs)
Time Frame: From study treatment initiation to Week 24
|
From study treatment initiation to Week 24
|
Proportion of participants with ≥1 log10 IU/mL decline from baseline in quantitative HBsAg (qHBsAg) after SLGN treatment at Week 24
Time Frame: At week 24
|
At week 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of participants with ≥1 log10 IU/mL decline from baseline in qHBsAg at any time during the study after SLGN treatment Initiation
Time Frame: Baseline though week 48
|
Baseline though week 48
|
Proportion of participants with ≥0.5 log10 IU/mL decline from baseline in qHBsAg after SLGN treatment at Week 24
Time Frame: At week 24
|
At week 24
|
Proportion of participants with ≥0.5 log10 IU/mL decline in qHBsAg from baseline at any time during the study after SLGN treatment initiation
Time Frame: Baseline though week 48
|
Baseline though week 48
|
Proportion of participants who achieve HBsAg loss after SLGN initiation and who sustain HBsAg loss during follow-up
Time Frame: Baseline though week 48
|
Baseline though week 48
|
Changes from baseline in qHBsAg levels at Weeks 4, 12, 24, 36, and 48
Time Frame: At week 4, 12, 24, 36 and 48
|
At week 4, 12, 24, 36 and 48
|
Proportion of HBeAg positive participants at baseline who lose HBeAg at any time during the study
Time Frame: Baseline though week 48
|
Baseline though week 48
|
Proportion of anti-HBe negative participants at baseline who develop anti-HBe at any time during the study
Time Frame: Baseline though week 48
|
Baseline though week 48
|
Proportion of hepatitis B surface antibody (anti-HBs) negative participants at baseline who develop anti-HBs at any time during the study
Time Frame: Baseline though week 48
|
Baseline though week 48
|
Detection of plasma HIV RNA >50 copies/mL at weeks 2, 4, 24, and 48
Time Frame: At Weeks 2, 4, 24 and 48
|
At Weeks 2, 4, 24 and 48
|
Detection of serum HBV DNA >50 IU/mL at weeks 2, 4, 24, and 48
Time Frame: At Weeks 2, 4, 24 and 48
|
At Weeks 2, 4, 24 and 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 5, 2023
Primary Completion (Estimated)
January 19, 2025
Study Completion (Estimated)
July 17, 2025
Study Registration Dates
First Submitted
September 9, 2022
First Submitted That Met QC Criteria
September 20, 2022
First Posted (Actual)
September 22, 2022
Study Record Updates
Last Update Posted (Actual)
April 18, 2024
Last Update Submitted That Met QC Criteria
April 16, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Disease Attributes
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Chronic Disease
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
Other Study ID Numbers
- A5394
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Individual participant data that underlie results in the publication, after deidentification
IPD Sharing Time Frame
Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH
IPD Sharing Access Criteria
With whom?
Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
For what types of analyses?
To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
By what mechanism will data be made available?
Researchers may submit a request for access to data using the AIDS Clinical Trials Group "Data Request" form at: https://actgnetwork.org/submit-a-proposal/.
Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States